

## 7 LITERATUR

### 7.1 Zitierte Literatur

- Agha, I.A., Rueda, J., Alvarez, A., Singer, G.G., Miller, B.W., Flavin, K., Lowell, J.A., Shenoy, S., Howard, T.K., Ramachandran, V., Irish, W., Schnitzle, M.A. & Brennan, D.C. (2002): Short course induction immunosuppression with thymoglobulin for renal transplant recipients. *Transplantation* **73**, 473-475.
- Anderson, J.E., Appelbaum, F.R., Fisher, L.D., Schoch, G., Shulman, H., Anasetti, C., Bensinger, W.I., Bryant, E., Buckner, C.D. & Doney, K. (1993): Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. *Blood* **82**, 677-681.
- Appelbaum, F.R. & Anderson, J. (1998): Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. *Leukemia* **12**, S25-29.
- Arnold, R., de Witte, T., van Biezen, A., Hermans, J., Jacobsen, N., Runde, V., Gratwohl, A. & Apperley, J.F. (1998): Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. *Bone Marrow Transplant* **21**, 1213-1216.
- Arns, W. & Weber, M. (2002): From acute to chronic rejection after kidney transplantation. *Med Klin* **97**, 609-613.
- Ashkenazi, A. & Dixit, V.M. (1999): Apoptosis control by death and decoy receptors. *Curr Opin Cell Biol* **11**, 255-260.
- ATCC (2002a): American Type Culture Collection, Cell Lines KG-1a, [www.atcc.org/SearchCatalogs/longview.cfm](http://www.atcc.org/SearchCatalogs/longview.cfm), Stand 14.11.2002.
- ATCC (2002b): American Type Culture Collection, Cell Lines U-937, [www.atcc.org/SearchCatalogs/longview.cfm](http://www.atcc.org/SearchCatalogs/longview.cfm), Stand 14.11.2002.
- Aul, C., Bowen, D. & Yoshida, Y. (1998a): Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. *Haematologica* **83**, 71-86.
- Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G. & Schneider, W. (1992): Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. *Leukemia* **6**, 52-59.
- Aul, C. & Germing, U. (1998b): Myelodysplastic syndromes. *Internist (Berl)* **39**, 1168-1180.
- Aul, C., Giagounidis, A., Germing, U. & Ganser, A. (2002): Myelodysplastic syndromes. Diagnosis and therapeutic strategies. *Med Klin* **97**, 666-676.
- Bacigalupo, A., Brand, R., Oneto, R., Bruno, B., Socie, G., Passweg, J., Locasciulli, A., Van Lint, M.T., Tichelli, A., McCann, S., Marsh, J., Ljungman, P., Hows, J., Marin, P. & Schrezenmeier, H. (2000a): Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy-The European Group for Blood and Marrow Transplantation experience. *Semin Hematol* **37**, 69-80.
- Bacigalupo, A., Broccia, G., Corda, G., Arcese, W., Carotenuto, M., Gallamini, A., Locatelli, F., Mori, P.G., Saracco, P. & Todeschini, G. (1995): Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA Working Party. *Blood* **85**, 1348-1353.

- Bacigalupo, A., Bruno, B., Saracco, P., Di Bona, E., Locasciulli, A., Locatelli, F., Gabbas, A., Dufour, C., Arcese, W., Testi, G., Broccia, G., Carotenuto, M., Coser, P., Barbui, T., Leoni, P. & Ferster, A. (2000b): Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midollo Osseo (GITMO). *Blood* **95**, 1931-1934.
- Bacigalupo, A., Hows, J., Gluckman, E., Nissen, C., Marsh, J., Van Lint, M.T., Congiu, M., De Planque, M.M., Ernst, P. & McCann, S. (1988): Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. *Br J Haematol* **70**, 177-182.
- Bacigalupo, A., Oneto, R., Bruno, B., Socie, G., Passweg, J., Locasciulli, A., Van Lint, M.T., Tichelli, A., McCann, S., Marsh, J., Ljungman, P., Hows, J., Marin, P. & Schrezenmeier, H. (2000c): Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. *Acta Haematol* **103**, 19-25.
- Bacigalupo, A., Piaggio, G., Figari, O., Tong, J., Sogno, G., Tedone, E., Sette, A., Ratto, M.R., Caciagli, P. & Badolati, G. (1991): Response of CFU-GM to increasing doses of rhGM-CSF in patients with aplastic anemia. *Exp Hematol* **19**, 829-832.
- Bacigalupo, A., Podesta, M. & Raffo, M. (1980): Lack of in vitro colony (CFU) formation and myelosuppressive activity in patients with severe aplastic anemia after autologous hematologic reconstitution. *Exp Hematol* **8**, 795-801.
- Barbano, G.C., Schenone, A., Roncella, S., Ghio, R., Corcione, A., Mori, P.G., Ferrarini, M. & Pistoia, V. (1988): Anti-lymphocyte globulin stimulates normal human T cells to proliferate and to release lymphokines in vitro. A study at the clonal level. *Blood* **72**, 956-963.
- Beaufigeau, M., Dumesnil, D., Carrier, M., White, M. & Pelletier, G.B. (1997): Seven-year experience with rabbit antithymocyte globulin after cardiac transplantation at the Montreal Heart Institute. *Transplant Proc* **29**, 10S-12S.
- Bellosillo, B., Colomer, D., Pons, G. & Gil, J. (1998): Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. *Br J Haematol* **100**, 142-146.
- Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1982): Proposals for the classification of the myelodysplastic syndromes. *Br J Haematol* **51**, 189-199.
- Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1985): Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. *Ann Intern Med* **103**, 620-625.
- Biesma, D., van den Tweel, J. & Verdonck, L. (1997): Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. *Cancer* **79**, 1548-1551.
- Biotest Pharma GmbH (1999): Tecelac, ATG vom Kaninchen. Dreieich.
- Boldin, M.P., Goncharov, T.M., Goltsev, Y.V. & Wallach, D. (1996): Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. *Cell* **85**, 803-815.

- Boldin, M.P., Varfolomeev, E.E., Pancer, Z., Mett, I.L., Camonis, J.H. & Wallach, D. (1995): A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. *J Biol Chem* **270**, 7795-7798.
- Bonnefoy-Bérard, N., Flacher, M. & Revillard, J.P. (1992a): Antiproliferative effect of antilymphocyte globulins on B cells and B-cell lines. *Blood* **79**, 2164-2170.
- Bonnefoy-Bérard, N., Fournel, S., Genestier, L., Flacher, M., Quemeneur, L. & Revillard, J.P. (1998): In vitro functional properties of antithymocyte globulins: clues for new therapeutic applications? *Transplant Proc* **30**, 4015-4017.
- Bonnefoy-Bérard, N., Genestier, L., Flacher, M., Rouault, J.P., Lizard, G., Mutin, M. & Revillard, J.P. (1994): Apoptosis induced by polyclonal antilymphocyte globulins in human B-cell lines. *Blood* **83**, 1051-1059.
- Bonnefoy-Bérard, N., Genestier, L., Preville, X. & Revillard, J.P. (1999): TNF alpha and CD95-L contribute to apoptosis of activated lymphocytes triggered by ATGs. *Transplant Proc* **31**, 775-777.
- Bonnefoy-Bérard, N. & Revillard, J.P. (1996): Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. *J Heart Lung Transplant* **15**, 435-442.
- Bonnefoy-Bérard, N., Verrier, B., Vincent, C. & Revillard, J.P. (1992b): Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins. *Immunology* **77**, 61-67.
- Bonnefoy-Bérard, N., Vincent, C. & Revillard, J.P. (1991): Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. *Transplantation* **51**, 669-673.
- Bonnefoy-Bérard, N., Vincent, C., Verrier, B. & Revillard, J.P. (1992c): Monocyte-independent T-cell activation by polyclonal antithymocyte globulins. *Cell Immunol* **143**, 272-283.
- Bourdage, J.S. & Hamlin, D.M. (1995): Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. *Transplantation* **59**, 1194-1200.
- Brancolini, C., Benedetti, M. & Schneider, C. (1995): Microfilament reorganization during apoptosis: the role of Gas2, a possible substrate for ICE-like proteases. *Embo J* **14**, 5179-5190.
- Brancolini, C., Lazarevic, D., Rodriguez, J. & Schneider, C. (1997): Dismantling cell-cell contacts during apoptosis is coupled to a caspase-dependent proteolytic cleavage of beta-catenin. *J Cell Biol* **139**, 759-771.
- Brodsky, R.A., Sensenbrenner, L.L. & Jones, R.J. (1996): Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. *Blood* **87**, 491-494.
- Bunn, D., Lea, C.K., Bevan, D.J., Higgins, R.M. & Hendry, B.M. (1996): The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. *Clin Nephrol* **45**, 29-32.
- Buzaid, A.C., Garewal, H.S. & Greenberg, B.R. (1986): Management of myelodysplastic syndromes. *Am J Med* **80**, 1149-1157.
- Cantarovich, D., Paineau, J., Hourmant, M., Baatard, R., Auvigne, J. & Souillou, J.P. (1990): Low incidence of rejection following combined kidney and pancreas transplantation. *Transplant Proc* **22**, 626-628.
- Carlo-Stella, C., Cazzola, M., Bergamaschi, G., Bernasconi, P., Dezza, L., Invernizzi, R. & Pedrazzoli, P. (1989): Growth of human hematopoietic colonies from patients with

- myelodysplastic syndromes in response to recombinant human granulocyte-macrophage colony-stimulating factor. *Leukemia* **3**, 363-366.
- Carson, D.A. & Ribeiro, J.M. (1993): Apoptosis and disease. *Lancet* **341**, 1251-1254.
- Casciola-Rosen, L.A., Miller, D.K., Anhalt, G.J. & Rosen, A. (1994): Specific cleavage of the 70-kDa protein component of the U1 small nuclear ribonucleoprotein is a characteristic biochemical feature of apoptotic cell death. *J Biol Chem* **269**, 30757-30760.
- Caserini, C., Pratesi, G., Tortoreto, M., Bedogne, B., Carenini, N., Supino, R., Perego, P., Righetti, S.C. & Zunino, F. (1997): Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies. *Clin Cancer Res* **3**, 955-961.
- Castedo, M., Hirsch, T., Susin, S.A., Zamzami, N., Marchetti, P., Macho, A. & Kroemer, G. (1996): Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. *J Immunol* **157**, 512-521.
- Cell Signaling Technology (2002): 2002 edition, 2002 catalog & technical reference. Seite 235; Cell Signaling Technology™. Beverly, MA, USA.
- CellQuest™ Software User's Guide (1996): Rev. A. Becton Dickinson Immunocytometry Systems. San Jose, CA, USA.
- Chen Chiao, Y.C., Gurudath Rao, K., Hook, J.W. 3rd, Krugh, T.R. & Sengupta, S.K. (1979): 7-Amino-actinomycin D complexes with deoxynucleotides as models for the binding of the drug to DNA. *Biopolymers* **18**, 1749-1762.
- Chen, C.L., Rawwas, J., Sorrell, A., Eddy, L. & Uckun, F.M. (2001): Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients. *Leuk Lymphoma* **42**, 317-327.
- Cheson, B.D., Zwiebel, J.A., Dancy, J. & Murgo, A. (2000): Novel therapeutic agents for the treatment of myelodysplastic syndromes. *Semin Oncol* **27**, 560-577.
- Chinnaiyan, A.M., Tepper, C.G., Seldin, M.F., O'Rourke, K., Kischkel, F.C., Hellbardt, S., Krammer, P.H., Peter, M.E. & Dixit, V.M. (1996): FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. *J Biol Chem* **271**, 4961-4965.
- Clark, K.R., Forsythe, J.L., Shenton, B.K., Lennard, T.W., Proud, G. & Taylor, R.M. (1993): Administration of ATG according to the absolute T lymphocyte count during therapy for steroid-resistant rejection. *Transpl Int* **6**, 18-21.
- Cohen, G.M. (1997): Caspases: the executioners of apoptosis. *Biochem J* **326**, 1-16.
- Cohen, J.R., Creger, W.P., Greenberg, P.L. & Schrier, S.L. (1979): Subacute myeloid leukemia: a clinical review. *Am J Med* **66**, 959-966.
- Cohen, S.M. (2002): Current immunosuppression in liver transplantation. *Am J Ther* **9**, 119-125.
- Cosimi, A. (1988): Antilymphocyte globulin and monoclonal antibodies, Morris PJ (ed). *Kidney Transplantation. Principles and Practice*, 3rd edition. WB Saunders. Philadelphia, PA, Seite 343.
- Cox, C., Killick, S., Patel, S., Elebute, M., Marsh, J., Gordon-Smith, E. & Gibson, F. (2000): In vitro proliferation and differentiation of megakaryocytic progenitors in patients with aplastic anemia, paroxysmal nocturnal hemoglobinuria, and the myelodysplastic syndromes. *Stem Cells* **18**, 428-434.
- Dansey, R. (2000): Myelodysplasia. *Curr Opin Oncol* **12**, 13-21.

- Deas, O., Dumont, C., MacFarlane, M., Rouleau, M., Hebib, C., Harper, F., Hirsch, F., Charpentier, B., Cohen, G.M. & Senik, A. (1998): Caspase-independent cell death induced by anti-CD2 or staurosporine in activated human peripheral T lymphocytes. *J Immunol* **161**, 3375-3383.
- Deeg, H.J., Loughran, T.P., Jr., Storb, R., Kennedy, M.S., Sullivan, K.M., Doney, K., Appelbaum, F.R. & Thomas, E.D. (1985): Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. *Transplantation* **40**, 162-166.
- Deeg, H.J., Shulman, H.M., Anderson, J.E., Bryant, E.M., Gooley, T.A., Slattery, J.T., Anasetti, C., Fefer, A., Storb, R. & Appelbaum, F.R. (2000): Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. *Blood* **95**, 1188-1194.
- Demuyneck, H., Verhoef, G.E., Zachee, P., Emonds, M.P., van der Schueren, E., van den Berghe, H., Vandenberghe, P., Casteels-Van Daele, M. & Boogaerts, M.A. (1996): Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. *Bone Marrow Transplant* **17**, 745-751.
- Di Bona, E., Rodeghiero, F., Bruno, B., Gabbas, A., Foa, P., Locasciulli, A., Rosanelli, C., Camba, L., Saracco, P., Lippi, A., Iori, A.P., Porta, F., De Rossi, G., Comotti, B., Iacopino, P., Dufour, C., Bacigalupo, A. & De Rossi, V. (1999): Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). *Br J Haematol* **107**, 330-334.
- Dirks, W., Schone, S., Uphoff, C., Quentmeier, H., Pradella, S. & Drexler, H.G. (1997): Expression and function of CD95 (FAS/APO-1) in leukaemia-lymphoma tumour lines. *Br J Haematol* **96**, 584-593.
- Doll, D., Kasper, L., Taetle, R. & List, A. (1998): Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes. *Leuk Res* **22**, 7-12.
- Doney, K., Leisenring, W., Storb, R. & Appelbaum, F.R. (1997): Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. *Ann Intern Med* **126**, 107-115.
- Dubey, S., Srivastava, A. & Nityanand, S. (2002): Induction of apoptosis of peripheral blood mononuclear cells by antithymocyte globulin (ATG) in aplastic anemia: an in vivo and in vitro study. *Ann Hematol* **81**, 249-253.
- Dumont, C., Durrbach, A., Bidere, N., Rouleau, M., Kroemer, G., Bernard, G., Hirsch, F., Charpentier, B., Susin, S.A. & Senik, A. (2000): Caspase-independent commitment phase to apoptosis in activated blood T lymphocytes: reversibility at low apoptotic insult. *Blood* **96**, 1030-1038.
- Earnshaw, W.C., Martins, L.M. & Kaufmann, S.H. (1999): Mammalian caspases: structure, activation, substrates, and functions during apoptosis. *Annu Rev Biochem* **68**, 383-424.
- Eaves, C. & Lambie, K. (1995): Atlas of Human Hematopoietic Colonies. StemCell Technologies Inc. .
- Efferth, T., Fabry, U. & Osieka, R. (1997): Apoptosis and resistance to daunorubicin in human leukemic cells. *Leukemia* **11**, 1180-1186.

- Ehrlich, P. (1888): Über einen Fall von Anämie mit Bemerkungen über regenerative Veränderungen des Knochenmarks. *Charité-Annalen* **13**, 301-309.
- Eiermann, T.H., Lambrecht, P. & Zander, A.R. (1999): Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. *Bone Marrow Transplant* **23**, 779-781.
- Ellis, R.E., Yuan, J.Y. & Horvitz, H.R. (1991): Mechanisms and functions of cell death. *Annu Rev Cell Biol* **7**, 663-698.
- Fadok, V.A., Bratton, D.L., Frasch, S.C., Warner, M.L. & Henson, P.M. (1998): The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. *Cell Death Differ* **5**, 551-562.
- Fisher, R.I., Silver, B.A., Vanhaelen, C.P., Jaffe, E.S. & Cossman, J. (1982): Objective regressions of T- and B-cell lymphomas in patients following treatment with anti-thymocyte globulin. *Cancer Res* **42**, 2465-2469.
- FreseniusAG (1998): Gebrauchsinformation: Anti-Human-T-Lymphozyten-Immunsrum. Bad Homburg v.d.H.
- Frickhofen, N. (1999): Aplastische Anämie, Thiemes Innere Medizin: TIM. Georg Thieme Verlag, Stuttgart New York, Seite 851-855.
- Frickhofen, N., Heimpel, H., Kaltwasser, J.P. & Schrezenmeier, H. (2002): Eleven years follow-up of a randomized trial comparing antithymocyte globulin with or without cyclosporine A for treatment of aplastic anemia. *Blood* **10**, 10.
- Frickhofen, N., Kaltwasser, J.P., Schrezenmeier, H., Raghavachar, A., Vogt, H.G., Herrmann, F., Freund, M., Meusers, P., Salama, A. & Heimpel, H. (1991): Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. *N Engl J Med* **324**, 1297-1304.
- Frickhofen, N. & Rosenfeld, S.J. (2000): Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine. *Semin Hematol* **37**, 56-68.
- Fuhrer, M., Bender-Gotze, C., Ebell, W., Friedrich, W. & Kohne, E. (1994): Treatment of aplastic anemia-aims and development of the SAA 94 pilot protocol. *Klin Padiatr* **206**, 289-295.
- Ganser, A., Seipelt, G. & Hoelzer, D. (1991): The role of GM-CSF, G-CSF, interleukin-3, and erythropoietin in myelodysplastic syndromes. *Am J Clin Oncol* **14**, S34-39.
- Garcia, S., Sanz, M.A., Amigo, V., Colomina, P., Carrera, M.D., Lorenzo, J.I. & Sanz, G.F. (1988): Prognostic factors in chronic myelodysplastic syndromes: a multivariate analysis in 107 cases. *Am J Hematol* **27**, 163-168.
- Gascon, P., Zoumbos, N.C., Scala, G., Djeu, J.Y., Moore, J.G. & Young, N.S. (1985): Lymphokine abnormalities in aplastic anemia: implications for the mechanism of action of antithymocyte globulin. *Blood* **65**, 407-413.
- Geddes, A.A., Bowen, D.T. & Jacobs, A. (1990): Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome. *Br J Haematol* **76**, 194-202.
- Genestier, L., Fournel, S., Flacher, M., Assossou, O., Revillard, J.P. & Bonnefoy-Bérard, N. (1998): Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. *Blood* **91**, 2360-2368.
- Gill, J.E., Jotz, M.M., Young, S.G., Modest, E.J. & Sengupta, S.K. (1975): 7-Amino-actinomycin D as a cytochemical probe. I. Spectral properties. *J Histochem Cytochem* **23**, 793-799.
- Gillio, A.P., Boulad, F., Small, T.N., Kernan, N.A., Reyes, B., Childs, B.H., Brochstein, J.A., Laver, J., Castro-Malaspina, H. & O'Reilly, R.J. (1997): Comparison of long-term

- outcome of children with severe aplastic anemia treated with immunosuppression versus bone marrow transplantation. *Biol Blood Marrow Transplant* **3**, 18-24.
- Gluckman, E., Horowitz, M.M., Champlin, R.E., Hows, J.M., Bacigalupo, A., Biggs, J.C., Camitta, B.M., Gale, R.P., Gordon-Smith, E.C. & Marmont, A.M. (1992): Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. *Blood* **79**, 269-275.
- Gomez-Morales, E., Martinez-Jaramillo, G., Sanchez-Valle, E., Valencia-Plata, I., Arana-Trejo, R.M., Castro, M.A., Pizzuto-Chavez, J. & Mayani, H. (1998): Deficient proliferation of myeloid, erythroid, and multipotent progenitor cells in long-term marrow cultures from patients with aplastic anemia treated with immunosuppressive therapy. *Am J Hematol* **59**, 149-155.
- Gordon-Smith, E. & Marsh, J.C. (1994): Bone marrow transplantation in the management of acquired aplastic anemia. *J Hematother* **3**, 238-243.
- Graziani, F., Van Lint, M.T., Dominiotto, A., Raiola, A.M., Di Grazia, C., Lamparelli, T., Gualandi, F., Bregante, S., Fiorone, M., Bruno, B. & Bacigalupo, A. (2002): Treatment of acute graft versus host disease with low dose-alternate day anti-thymocyte globulin. *Haematologica* **87**, 973-978.
- Greco, B., Bielory, L., Stephany, D., Hsu, S.M., Gascon, P., Nienhuis, A. & Young, N. (1983): Antithymocyte globulin reacts with many normal human cell types. *Blood* **62**, 1047-1054.
- Greenberg, P.L., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997): International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood* **89**, 2079-2088.
- Greenberg, P.L. (1983): The smoldering myeloid leukemic states: clinical and biologic features. *Blood* **61**, 1035-1044.
- Greenberg, P.L. (1987): Biologic nature of the myelodysplastic syndromes. *Acta Haematol* **78 Suppl 1**, 94-99.
- Greenberg, P.L. (1991): Treatment of myelodysplastic syndromes. *Blood Rev* **5**, 42-50.
- Greenberg, P.L. (1992): In vitro marrow culture studies in the myelodysplastic syndromes. *Semin Oncol* **19**, 34-46.
- Greenberg, P.L. (1996): Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. *Semin Hematol* **33**, 163-175.
- Greenberg, P.L. (1998): Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. *Leuk Res* **22**, 1123-1136.
- Greenberg, P.L., Sanz, G.F. & Sanz, M.A. (1999): Prognostic scoring systems for risk assessment in myelodysplastic syndromes. *Forum (Genova)* **9**, 17-31.
- Guinan, E.C. (1997): Clinical aspects of aplastic anemia. *Hematol Oncol Clin North Am* **11**, 1025-1044.
- Guttmann, R.D., Caudrelier, P., Alberici, G. & Touraine, J.L. (1997): Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. *Transplant Proc* **29**, 24S-26S.
- Hamilton-Peterson, J. (1949): Pre-leukemia anemia. *Acta Haematol* **2**, 309-316.
- Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999): World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical

- Advisory Committee meeting-Airlie House, Virginia, November 1997. *J Clin Oncol* **17**, 3835-3849.
- Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (2000): The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. *Histopathology* **36**, 69-86.
- Haughland, R.P. (2001): [www.probes.com/handbook/](http://www.probes.com/handbook/), Handbook of Fluorescent Probes and Research Products, *Eight Edition*, Molecular Probes, Inc., Leiden, Niederlande, Stand 14.11.2002.
- He, L. & Liu, G.Q. (2002): Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood-brain barrier. *Acta Pharmacol Sin* **23**, 423-429.
- Hellstrom-Lindberg, E. (1999): Treatment of adult myelodysplastic syndromes. *Int J Hematol* **70**, 141-154.
- Hellstrom-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I.M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J.M., Winqvist, I., Oberg, G., Osterborg, A. & Ost, A. (1998): Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. *Blood* **92**, 68-75.
- Herold, G. & Mitarbeiter (2000): Aplastische Anämie, Innere Medizin. Köln, Seite 43-46.
- Hirai, H. (2002): Molecular pathogenesis of MDS. *Int J Hematol* **76**, 213-221.
- Hirst, W.J. & Mufti, G.J. (1993): Management of myelodysplastic syndromes. *Br J Haematol* **84**, 191-196.
- Hoelzer, D. & Seipelt, G. (1998): Myelodysplastische Syndrome, Leukämietherapie. UNI-MED Verlag, 1.Auflage, Bremen, Seite 38-47.
- Homburg, C.H., de Haas, M., von dem Borne, A.E., Verhoeven, A.J., Reutelingsperger, C.P. & Roos, D. (1995): Human neutrophils lose their surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis in vitro. *Blood* **85**, 532-540.
- Horan, P.K. & Slezak, S.E. (1989): Stable cell membrane labelling. *Nature* **340**, 167-168.
- Hu, S., Snipas, S.J., Vincenz, C., Salvesen, G. & Dixit, V.M. (1998): Caspase-14 is a novel developmentally regulated protease. *J Biol Chem* **273**, 29648-29653.
- Huang, A.T. & Mold, N.G. (1994): The role of CD45RO in antithymocyte globulin's stimulation of primitive haemopoietic cells. *Br J Haematol* **88**, 643-646.
- Huang, A.T., Mold, N.G. & Zhang, S.F. (1987): Antithymocyte globulin stimulates human hematopoietic progenitor cells. *Proc Natl Acad Sci U S A* **84**, 5942-5946.
- Hug, H. (1997): Fas-mediated apoptosis in tumor formation and defense. *Biol Chem* **378**, 1405-1412.
- Hunter, R.F., Mold, N.G., Mitchell, R.B. & Huang, A.T. (1985): Differentiation of normal marrow and HL60 cells induced by antithymocyte globulin. *Proc Natl Acad Sci U S A* **82**, 4823-4827.
- Institut Mérieux GmbH (1994): Thymoglobulin Mérieux: Anti-T-Zell-Immunglobulin aus dem Serum immunisierter Kaninchen. Institut Mérieux GmbH. Leimen.
- Institut Mérieux Transplant GmbH (1994): Gebrauchsinformation Lymphoglobulin Mérieux: Anti-T-Zell-Immunserum vom Pferd. Leimen.

- Jarosqueski, M.J. & Heller, R. (1997): Flow Cytometry Protocols, Methods in Molecular Biology. Humana Press Inc. Totowa, New Jersey, USA.
- Johnstone, R.W., Ruefli, A.A. & Smyth, M.J. (2000): Multiple physiological functions for multidrug transporter P-glycoprotein? *Trends Biochem Sci* **25**, 1-6.
- Jonasova, A., Neuwirtova, R., Cermak, J., Vozobulova, V., Mocikova, K., Siskova, M. & Hochova, I. (1998): Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. *Br J Haematol* **100**, 304-309.
- Jones, G.E. (1996): Human Cell Culture Protocols, Methods in Molecular Medicine. Humana Press Inc. Totowa, New Jersey, USA.
- Kato, K. & Radbruch, A. (1993): Isolation and characterization of CD34+ hematopoietic stem cells from human peripheral blood by high-gradient magnetic cell sorting. *Cytometry* **14**, 384-392.
- Kawano, Y., Nissen, C., Gratwohl, A. & Speck, B. (1988): Immunostimulatory effects of different antilymphocyte globulin preparations: a possible clue to their clinical effect. *Br J Haematol* **68**, 115-119.
- Kawano, Y., Nissen, C., Gratwohl, A., Wursch, A. & Speck, B. (1990): Cytotoxic and stimulatory effects of antilymphocyte globulin (ALG) on hematopoiesis. *Blut* **60**, 297-300.
- Kawano, Y., Takaue, Y., Hirao, A., Watanabe, T., Abe, T., Shimizu, T., Sato, J., Saito, S., Kitamura, T. & Takaku, F. (1992): Production of interleukin 3 and granulocyte-macrophage colony-stimulating factor from stimulated blood mononuclear cells in patients with aplastic anemia. *Exp Hematol* **20**, 1125-1128.
- Kerr, J.F., Wyllie, A.H. & Currie, A.R. (1972): Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br J Cancer* **26**, 239-257.
- Killick, S.B., Marsh, J., Cavenagh, J., Mijovic, A., Mufti, G., Gordon-Smith, E. & Bowen, D. (1999): Antithymocyte globulin for the treatment of Patients with 'low risk' Myelodysplastic Syndromes. *Blood* **94**, 306.
- Killick, S.B., Cox, C.V., Marsh, J.C., Gordon-Smith, E.C. & Gibson, F.M. (2000a): Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti-thymocyte globulin: examination of the role of the Fas-Fas-L interaction. *Br J Haematol* **111**, 1164-1169.
- Killick, S.B. & Marsh, J.C. (2000b): Aplastic anaemia: management. *Blood Rev* **14**, 157-171.
- Killick, S.B., Marsh, J.C., Gordon-Smith, E.C., Sorlin, L. & Gibson, F.M. (2000c): Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia. *Br J Haematol* **108**, 582-591.
- Kim, K.M., Lee, K., Hong, Y.S. & Park, H.Y. (2000): Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells. *Exp Mol Med* **32**, 246-254.
- Kitamura, K., Minami, Y., Yamamoto, K., Akao, Y., Kiyoi, H., Saito, H. & Naoe, T. (2000): Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. *Leukemia* **14**, 1743-1750.
- Knauf, W.U., Berdel, W.E., Ho, A.D., Kreuser, E.D. & Thiel, E. (1994): Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. *Leuk Lymphoma* **12**, 421-425.
- Knospe, W.H. & Gregory, S.A. (1971): Smoldering acute leukemia. Clinical and cytogenetic studies in six patients. *Arch Intern Med* **127**, 910-918.
- Koeffler, H.P. (1983): Induction of differentiation of human acute myelogenous leukemia cells. Therapeutic implications. *Blood* **62**, 709-721

- Kojima, S., Horibe, K., Inaba, J., Yoshimi, A., Takahashi, Y., Kudo, K., Kato, K. & Matsuyama, T. (2000): Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. *Br J Haematol* **111**, 321-328.
- Kothakota, S., Azuma, T., Reinhard, C., Klippel, A., Tang, J., Chu, K., McGarry, T.J., Kirschner, M.W., Koths, K., Kwiatkowski, D.J. & Williams, L.T. (1997): Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. *Science* **278**, 294-298.
- Krasinskas, A.M., Kreisel, D., Acker, M.A., Bavaria, J.E., Pochettino, A., Kotloff, R.M., Arcasoy, S., Blumenthal, N., Kamoun, M., Moore, J.S. & Rosengard, B.R. (2002): CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. *Transplantation* **73**, 1339-1341.
- Kroger, N., Zabelina, T., Kruger, W., Renges, H., Stute, N., Rischewski, J., Sonnenberg, S., Ayuk, F., Togel, F., Schade, U., Fiegel, H., Erttmann, R., Loliger, C. & Zander, A.R. (2002): In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. *Bone Marrow Transplant* **29**, 683-689.
- Kuriya, S., Murai, K., Miyairi, Y., Utsugisawa, T., Narigasawa, Y., Ito, T., Shimosegawa, K. & Ishida, Y. (1996): A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study. *Cancer* **78**, 422-426.
- Lambertenghi-Delilieri, G., Orazi, A., Luksch, R., Annaloro, C. & Soligo, D. (1991): Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinicopathological entity. *Br J Haematol* **78**, 161-166.
- Landowski, T.H., Moscinski, L., Burke, R., Buyuksal, I., Painter, J.S., Goldstein, S. & Dalton, W.S. (2001): CD95 antigen mutations in hematopoietic malignancies. *Leuk Lymphoma* **42**, 835-846.
- Lawlor, E.R., Anderson, R.A., Davis, J.H., Fryer, C.J., Pritchard, S.L., Rogers, P.C., Wu, J.K. & Schultz, K.R. (1997): Immunosuppressive therapy: a potential alternative to bone marrow transplantation as initial therapy for acquired severe aplastic anemia in childhood? *J Pediatr Hematol Oncol* **19**, 115-123.
- Lazebnik, Y.A., Kaufmann, S.H., Desnoyers, S., Poirier, G.G. & Earnshaw, W.C. (1994): Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. *Nature* **371**, 346-347.
- Lecoeur, H., Ledru, E. & Gougeon, M.L. (1998): A cytofluorometric method for the simultaneous detection of both intracellular and surface antigens of apoptotic peripheral lymphocytes. *J Immunol Methods* **217**, 11-26.
- Lecoeur, H., Ledru, E., Prevost, M.C. & Gougeon, M.L. (1997): Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods. *J Immunol Methods* **209**, 111-123.
- Lepelley, P., Grardel, N., Erny, O., Iaru, T., Obein, V., Cosson, A. & Fenaux, P. (1998): Fas/APO-1 (CD95) expression in myelodysplastic syndromes. *Leuk Lymphoma* **30**, 307-312.
- Lindl, T. & Bauer, J. (1989): Zell- und Gewebekultur, Einführung in die Grundlagen sowie ausgewählte Methoden und Anwendungen. Gustav Fischer Verlag. Stuttgart New York.

- Linman, J.W. & Saarni, M.I. (1974): The preleukemic syndrome. *Semin Hematol* **11**, 93-100.
- List, A.F. (2002): New approaches to the treatment of myelodysplasia. *Oncologist* **7**, 39-49.
- Liston, P., Roy, N., Tamai, K., Lefebvre, C., Baird, S., Cherton-Horvat, G., Farahani, R., McLean, M., Ikeda, J.E., MacKenzie, A. & Korneluk, R.G. (1996): Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. *Nature* **379**, 349-353.
- Löffler, G. & Petrides, P.E. (1997): *Krebstherapie, Biochemie und Pathobiochemie*. Springer-Verlag, 5. Auflage, Berlin Heidelberg New York, Seite 1111.
- MacMillan, M.L., Weisdorf, D.J., Davies, S.M., DeFor, T.E., Burns, L.J., Ramsay, N.K., Wagner, J.E. & Blazar, B.R. (2002): Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. *Biol Blood Marrow Transplant* **8**, 40-46.
- Marsh, J., Schrezenmeier, H., Marin, P., Ilhan, O., Ljungman, P., McCann, S., Socie, G., Tichelli, A., Passweg, J., Hows, J., Raghavachar, A., Locasciulli, A. & Bacigalupo, A. (1999): Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. *Blood* **93**, 2191-2195.
- Marsh, J.C. (2000): Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemia. *Semin Hematol* **37**, 81-90.
- Marsh, J.C. & Gordon-Smith, E.C. (1998): Treatment options in severe aplastic anaemia. *Lancet* **351**, 1830-1831.
- Martin, S.J. & Green, D.R. (1995a): Apoptosis and cancer: the failure of controls on cell death and cell survival. *Crit Rev Oncol Hematol* **18**, 137-153.
- Martin, S.J., Reutelingsperger, C.P., McGahon, A.J., Rader, J.A., van Schie, R.C., LaFace, D.M. & Green, D.R. (1995b): Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. *J Exp Med* **182**, 1545-1556.
- Martinez-Jaramillo, G., Flores-Figueroa, E., Sanchez-Valle, E., Gutierrez-Espindola, G., Gomez-Morales, E., Montesinos, J.J., Flores-Guzman, P., Chavez-Gonzalez, A., Alvarado-Moreno, J.A. & Mayani, H. (2002): Comparative analysis of the in vitro proliferation and expansion of hematopoietic progenitors from patients with aplastic anemia and myelodysplasia. *Leuk Res* **26**, 955-963.
- Martinez-Jaramillo, G., Gomez-Morales, E. & Mayani, H. (1999): Effect of recombinant human granulocyte macrophage-colony stimulating factor in long-term marrow cultures from patients with aplastic anemia. *Am J Hematol* **61**, 107-114.
- Maschek, H., Kaloutsi, V., Rodriguez-Kaiser, M., Werner, M., Choritz, H., Mainzer, K., Dietzfelbinger, M. & Georgii, A. (1993): Hypoplastic myelodysplastic syndrome: incidence, morphology, cytogenetics, and prognosis. *Ann Hematol* **66**, 117-122.
- Masey, J. (1997): The myelodysplastic syndromes. *Br J Biomed Sci* **54**, 65-70.
- Mathé, G., Amiel, J., & Schwarzenberg, L. (1970): Bone marrow graft in man after conditioning by antilymphocytic serum. *BMJ* **2**, 131-136.
- Merion, R.M., Howell, T. & Bromberg, J.S. (1998): Partial T-cell activation and energy induction by polyclonal antithymocyte globulin. *Transplantation* **65**, 1481-1489.
- Miltenyi, S., Guth, S. & Radbruch, A. (1994): Isolation von CD34+ hematopoietic progenitor cells by high gradient magnetic cell sorting (MACS), Wunder E, Sovalat H, Hénon PR, eds Hematopoietic Stem Cells. Dayton, OH. AlphaMed Press, 201-213.

- Miltenyi, S., Muller, W., Weichel, W. & Radbruch, A. (1990): High gradient magnetic cell separation with MACS. *Cytometry* **11**, 231-238.
- Moebius, U., Herrmann, F., Hercend, T. & Meuer, S.C. (1991): Clonal analysis of CD4+/CD8+ T cells in a patient with aplastic anemia. *J Clin Invest* **87**, 1567-1574.
- Moisan, E., Arbour, S., Nguyen, N., Hebert, M.J., Girard, D., Bernier, J., Fournier, M. & Kouassi, E. (2002): Prolongation of human neutrophil survival by low-level mercury via inhibition of spontaneous apoptosis. *J Toxicol Environ Health A* **65**, 183-203.
- Molldrem, J.J., Caples, M., Mavroudis, D., Plante, M., Young, N. & Barrett, A. (1997): Antithymocyte globulin for patients with myelodysplastic syndrome. *Br J Haematol* **99**, 699-705.
- Molldrem, J.J., Jiang, Y.Z., Stetler-Stevenson, M., Mavroudis, D., Hensel, N. & Barrett, A.J. (1998): Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. *Br J Haematol* **102**, 1314-1322.
- Molldrem, J.J., Leifer, E., Bahceci, E., Sauntharajah, Y., Rivera, M., Dunbar, C., Liu, J., Nakamura, R., Young, N.S. & Barrett, A.J. (2002): Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. *Ann Intern Med* **137**, 156-163.
- Mollereau, B., Deckert, M., Deas, O., Rieux-Laucat, F., Hirsch, F., Bernard, A., Fischer, A., Lynch, D.H., Charpentier, B., Le Deist, F. & Senik, A. (1996): CD2-induced apoptosis in activated human peripheral T cells: a Fas-independent pathway that requires early protein tyrosine phosphorylation. *J Immunol* **156**, 3184-3190.
- Mongkonsritragoon, W., Kimlinger, T., Ahmann, G. & Greipp, P.R. (1998): Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis? *Leuk Lymphoma* **29**, 577-584.
- Muller, T.F., Grebe, S.O., Neumann, M.C., Heymanns, J., Radsak, K., Sprenger, H. & Lange, H. (1997): Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. *Transplantation* **64**, 1432-1437.
- Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J.D., Zhang, M., Gentz, R., Mann, M., Krammer, P.H., Peter, M.E. & Dixit, V.M. (1996): FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. *Cell* **85**, 817-827.
- Muzio, M., Salvesen, G.S. & Dixit, V.M. (1997): FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens. *J Biol Chem* **272**, 2952-2956.
- Nachbaur, D., Eibl, B., Kropshofer, G., Meister, B., Mitterschiffthaler, A., Schennach, H., Fischer, G., Kopp, M., Gunsilius, E. & Gastl, G. (2002): In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation. *J Hematother Stem Cell Res* **11**, 731-737.
- Nagata, S. (1997): Apoptosis by death factor. *Cell* **88**, 355-365.
- Najarian, J.S., Simmons, R.L., Condie, R.M., Thompson, E.J., Fryd, D.S., Howard, R.J., Matas, A.J., Sutherland, D.E., Ferguson, R.M. & Schmidtke, J.R. (1976): Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors. *Ann Surg* **184**, 352-368.

- Nakaya, K., Chou, S., Kaneko, M. & Nakamura, Y. (1991): Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells. *Jpn J Cancer Res* **82**, 184-191.
- Negrin, R.S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., Krantz, S. & Greenberg, P.L. (1996): Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. *Blood* **87**, 4076-4081.
- Nissen, C. (1991): The Pathophysiology of Aplastic Anemia. *Semin Hematol* **28**, 313-318.
- Nissen-Druey, C. (1990): Pathophysiology of aplastic anemia. *Blood Rev* **4**, 97-102.
- O'Donoghue, D.J., Johnson, R.W., Mallick, N.P., Gokal, R., Ballardie, F.W., Bakran, A., Pearson, R. & Scott, P. (1989): Rabbit anti-thymocyte globulin treatment of steroid resistant rejection in renal allograft recipients immunosuppressed with cyclosporine A. *Transplant Proc* **21**, 1736-1737.
- Ogata, K., Yamada, T., Ito, T., Gomi, S., Tanabe, Y., Ohki, I., Dan, K. & Nomura, T. (1992): Low-dose etoposide: a potential therapy for myelodysplastic syndromes. *Br J Haematol* **82**, 354-357.
- Ormerod, M.G. (1994): Flow Cytometry: A Practical Approach, *2nd edition*. IRL Press at Oxford University. Oxford, England.
- Owens, M.A. & Loken, M.R. (1995): Flow Cytometry Principles for Clinical Laboratory Practice. Wiley-Liss. New York, NY, USA.
- Paquette, R.L., Tebyani, N., Frane, M., Ireland, P., Ho, W., Champlin, R. & Nimer, S. (1995): Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. *Blood* **85**, 283-290.
- Paquette, R.L. (2002): Diagnosis and management of aplastic anemia and myelodysplastic syndrome. *Oncology (Huntingt)* **16**, 153-161.
- Parker, J.E., Fishlock, K.L., Mijovic, A., Czepulkowski, B., Pagliuca, A. & Mufti, G.J. (1998): 'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. *Br J Haematol* **103**, 1075-1082.
- Philpott, N.J., Scopes, J., Marsh, J.C., Gordon-Smith, E.C. & Gibson, F.M. (1995): Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. *Exp Hematol* **23**, 1642-1648.
- Philpott, N.J., Turner, A.J., Scopes, J., Westby, M., Marsh, J.C., Gordon-Smith, E.C., Dalgleish, A.G. & Gibson, F.M. (1996): The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. *Blood* **87**, 2244-2251.
- Pistillo, M.P., Tazzari, P.L., Bonifazi, F., Bandini, G., Kato, T., Matsui, T., Nishioka, K., Conte, R. & Ferrara, G.B. (2002): Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients. *Transplantation* **73**, 1295-1302.
- Pitcher, L.A., Hann, I.M., Evans, J.P., Veys, P., Chessells, J.M. & Webb, D.K. (1999): Improved prognosis for acquired aplastic anaemia. *Arch Dis Child* **80**, 158-162.
- Poirier, J. (1997): Apoptosis Techniques and Protocols, Neuromethods. Humana Press Inc. Totowa, New Jersey, USA.
- Pu, J., Lou, F. & Zhou, Q. (1999): In vitro reversal effect of cyclosporin A in combination with cytokines on multidrug resistant cell line K562/A02. *Zhonghua Yi Xue Za Zhi* **79**, 224-226.

- Radbruch, A. (1992): Flow Cytometry and Cell Sorting, *2nd edition*. Springer-Verlag. New York, NY, USA.
- Raefsky, E.L., Gascon, P., Gratwohl, A., Speck, B. & Young, N.S. (1986): Biological and immunological characterization of ATG and ALG. *Blood* **68**, 712-719.
- Rajapaksa, R., Ginzton, N., Rott, L.S. & Greenberg, P.L. (1996): Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. *Blood* **88**, 4275-4287.
- Rameshwar, P. & Gascon, P. (1992): Release of interleukin-1 and interleukin-6 from human monocytes by antithymocyte globulin: requirement for de novo synthesis. *Blood* **80**, 2531-2538.
- Rano, T.A., Timkey, T., Peterson, E.P., Rotonda, J., Nicholson, D.W., Becker, J.W., Chapman, K.T. & Thornberry, N.A. (1997): A combinatorial approach for determining protease specificities: application to interleukin-1beta converting enzyme (ICE). *Chem Biol* **4**, 149-155.
- Raza, A., Mundle, S., Shetty, V., Alvi, S., Chopra, H., Span, L., Parcharidou, A., Dar, S., Venugopal, P., Borok, R., Gezer, S., Showel, J., Loew, J., Robin, E., Rifkin, S., Alston, D., Hernandez, B., Shah, R., Kaizer, H. & Gregory, S. (1996): Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. *Int J Hematol* **63**, 265-278.
- Rebellato, L.M., Gross, U., Verbanac, K.M. & Thomas, J.M. (1994): A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. *Transplantation* **57**, 685-694.
- Regan, J.F., Lyonais, C., Campbell, K., Smith, L.V. & Buelow, R. (2001): Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. *Transpl Immunol* **9**, 29-36.
- Richert-Boe, K.E. & Bagby, G.C., Jr. (1992): In vitro hematopoiesis in myelodysplasia: liquid and soft-gel culture studies. *Hematol Oncol Clin North Am* **6**, 543-556.
- Rius, C., Zorrilla, A.R., Cabanas, C., Mata, F., Bernabeu, C. & Aller, P. (1991): Differentiation of human promonocytic leukemia U-937 cells with DNA topoisomerase II inhibitors: induction of vimentin gene expression. *Mol Pharmacol* **39**, 442-448.
- Robinson, J.P., Darzynkiewicz, Z., Dean, P., Orfao, A., Rabinovitch, P., Tanke, H. & Wheelless, L. (1999): Current Protocols in Cytometry. Wiley & Sons, Inc. New York, NY, USA.
- Rojewski, M.T., Baldus, C., Knauf, W., Thiel, E. & Schrezenmeier, H. (2002): Dual effects of arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. *Br J Haematol* **116**, 555-563.
- Rosenfeld, S., Kimball, J., Vining, D. & Young, N. (1995): Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. *Blood* **85**, 3058-3065.
- Rothe, M., Pan, M.G., Henzel, W.J., Ayres, T.M. & Goeddel, D.V. (1995): The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. *Cell* **83**, 1243-1252.
- Roy, N., Mahadevan, M.S., McLean, M., Shutler, G., Yaraghi, Z., Farahani, R., Baird, S., Besner-Johnston, A., Lefebvre, C. & Kang, X. (1995): The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. *Cell* **80**, 167-178.

- Runde, V., de Witte, T., Arnold, R., Gratwohl, A., Hermans, J., van Biezen, A., Niederwieser, D., Labopin, M., Walter-Noel, M.P., Bacigalupo, A., Jacobsen, N., Ljungman, P., Carreras, E., Kolb, H.J., Aul, C. & Apperley, J. (1998): Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant* **21**, 255-261.
- Salih, H.R., Starling, G.C., Brandl, S.F., Pelka-Fleischer, R., Haferlach, T., Hiddemann, W., Kiener, P.A. & Nuessler, V. (2002): Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression. *Br J Haematol* **117**, 76-85.
- Sambrook, J., Fritsch, E.F. & Maniatis, T. (1989): Molecular Cloning: A Laboratory Manual, 2nd edition. Cold Spring Harbour Laboratory Press. Cold Spring Harbour, New York, USA.
- Sanz, G.F., Sanz, M.A. & Greenberg, P.L. (1998): Prognostic factors and scoring systems in myelodysplastic syndromes. *Haematologica* **83**, 358-368.
- Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K.J., Debatin, K.M., Krammer, P.H. & Peter, M.E. (1998): Two CD95 (APO-1/Fas) signaling pathways. *Embo J* **17**, 1675-1687.
- Schmid, I., Uittenbogaart, C.H. & Giorgi, J.V. (1994a): Sensitive method for measuring apoptosis and cell surface phenotype in human thymocytes by flow cytometry. *Cytometry* **15**, 12-20.
- Schmid, I., Uittenbogaart, C.H., Keld, B. & Giorgi, J.V. (1994b): A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. *J Immunol Methods* **170**, 145-157.
- Schmitt-Graeff, A., Mattern, D., Kohler, H., Hezel, J. & Lubbert, M. (2000): Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis. *Pathologe* **21**, 1-15.
- Schrezenmeier, H., Marin, P., Raghavachar, A., McCann, S., Hows, J., Gluckman, E., Nissen, C., van't Veer-Korthof, E.T., Ljungman, P. & Hinterberger, W. (1993): Relapse of aplastic anaemia after immunosuppressive treatment: a report from the European Bone Marrow Transplantation Group SAA Working Party. *Br J Haematol* **85**, 371-377.
- Schrezenmeier, H., Mönich, T., Rojewski, M. & Thiel, E. (2001): Effects of antithymocyte globulin in myeloid cells: induction of apoptosis, activation of caspases and inhibition of proliferation rate. *Onkologie* **24**, 53.
- Schultz, J.C. & Shahidi, N.T. (1994): Detection of tumor necrosis factor-alpha in bone marrow plasma and peripheral blood plasma from patients with aplastic anemia. *Am J Hematol* **45**, 32-38.
- Schwartz, P.S. & Waxman, D.J. (2001): Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. *Mol Pharmacol* **60**, 1268-1279.
- Shield, C.F., Edwards, E.B., Davies, D.B. & Daily, O.P. (1997): Antilymphocyte induction therapy in cadaver renal transplantation: a retrospective, multicenter United Network for Organ Sharing Study. *Transplantation* **63**, 1257-1263.
- Shimazaki, C., Uchiyama, H., Fujita, N., Araki, S., Sudo, Y., Yamagata, N., Ashihara, E., Goto, H., Inaba, T. & Haruyama, H. (1995): Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation. *Exp Hematol* **23**, 1497-1502.

- Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. & Or, R. (1998): Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. *Blood* **91**, 756-763.
- Smith, A.G., O'Reilly, R.J., Hansen, J.A. & Martin, P.J. (1985): Specific antibody-blocking activities in antilymphocyte globulin as correlates of efficacy for the treatment of aplastic anemia. *Blood* **66**, 721-723.
- Smith, C., Farrah, T. & Googwin, R. (1994): The TNF Receptor superfamily of cellular and viral proteins: activation, costimulation and death. *Cell* **76**, 959-962.
- Socie, G., Henry-Amar, M., Bacigalupo, A., Hows, J., Tichelli, A., Ljungman, P., McCann, S.R., Frickhofen, N., Van't Veer-Korthof, E. & Gluckman, E. (1993): Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. *N Engl J Med* **329**, 1152-1157.
- Socie, G., Rosenfeld, S., Frickhofen, N., Guckman, E. & Tichelli, A. (2000): Late clonal diseases of treated aplastic anemia. *Semin Haematol* **37**, 91-101.
- Soldani, C., Lazze, M.C., Bottone, M.G., Tognon, G., Biggiogera, M., Pellicciari, C.E. & Scovassi, A.I. (2001): Poly(ADP-ribose) polymerase cleavage during apoptosis: when and where? *Exp Cell Res* **269**, 193-201.
- Souviron Rodriguez, A., Ruiz Gomez, M.J., Morales Moreno, J.A. & Martinez Morillo, M. (1997): Multidrug resistance (MDR) in oncology. *An Med Interna* **14**, 145-153.
- Sperandio, S., de Belle, I. & Bredesen, D.E. (2000): An alternative, nonapoptotic form of programmed cell death. *Proc Natl Acad Sci U S A* **97**, 14376-14381.
- Stadler, M., Germing, U., Kliche, K.O., Josten, K.M., Kuse, R., Hofman, W.K., Anders, O., Denzlingert, C., Novotny, J., Eiermacher, H., Schrezenmeier, H., Verbeek, W., Aul, C. & Ganser, A. (2000): Anti-Lymphocyte versus Anti-Thymocyte Globulin in low-risk Myelodysplastic Syndromes: A phase II Study. *Blood* **96**, 265b.
- StemCell Technologies (2003): Colony Assay of Hematopoietic Cells using Methylcellulose Medium, [www.stemcell.com/stemcell/html/product\\_Pages/literature/F\\_Product\\_Literature.html](http://www.stemcell.com/stemcell/html/product_Pages/literature/F_Product_Literature.html), Stand 01.03.03.
- Stepczynska, A., Lauber, K., Engels, I.H., Janssen, O., Kabelitz, D., Wesselborg, S. & Schulze-Osthoff, K. (2001): Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation. *Oncogene* **20**, 1193-1202.
- Storb, R., Etzioni, R., Anasetti, C., Appelbaum, F.R., Buckner, C.D., Bensinger, W., Bryant, E., Clift, R., Deeg, H.J. & Doney, K. (1994): Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. *Blood* **84**, 941-949.
- Storb, R., Leisenring, W., Anasetti, C., Appelbaum, F.R., Buckner, C.D., Bensinger, W.I., Chauncey, T., Clift, R.A., Deeg, H.J., Doney, K.C., Flowers, M.E., Hansen, J.A., Martin, P.J., Sanders, J.E., Sullivan, K.M. & Witherspoon, R.P. (1997): Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. *Blood* **89**, 3890-3891.

- Stute, N., Santana, V.M., Rodman, J.H., Schell, M.J., Ihle, J.N. & Evans, W.E. (1992): Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. *Blood* **79**, 2849-2854.
- Sundstorm, C. & Nilsson, K. (1976): Establishment and characterisation of a human histiocytic lymphoma cell line (U937). *Int. J. Cancer* **17**, 656-577.
- Swinnen, L.J., Costanzo-Nordin, M.R., Fisher, S.G., O'Sullivan, E.J., Johnson, M.R., Heroux, A.L., Dizikes, G.J., Pifarre, R. & Fisher, R.I. (1990): Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. *N Engl J Med* **323**, 1723-1728.
- Szczecz, L.A., Berlin, J.A., Aradhye, S., Grossman, R.A. & Feldman, H.I. (1997): Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. *J Am Soc Nephrol* **8**, 1771-1777.
- Szczecz, L.A., Berlin, J.A. & Feldman, H.I. (1998): The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. *Ann Intern Med* **128**, 817-826.
- Taniguchi, Y., Frickhofen, N., Raghavachar, A., Digel, W. & Heimpel, H. (1990): Antilymphocyte immunoglobulins stimulate peripheral blood lymphocytes to proliferate and release lymphokines. *Eur J Haematol* **44**, 244-251.
- Tchervenkov, J., Flemming, C., Guttman, R.D. & des Gachons, G. (1997): Use of thymoglobulin induction therapy in the prevention of acute graft rejection episodes following liver transplantation. *Transplant Proc* **29**, 13S-15S.
- Teramura, M., Kobayashi, S., Iwabe, K., Yoshinaga, K. & Mizoguchi, H. (1997): Mechanism of action of antithymocyte globulin in the treatment of aplastic anaemia: in vitro evidence for the presence of immunosuppressive mechanism. *Br J Haematol* **96**, 80-84.
- Teramura, M. & Mizoguchi, H. (1996): Special Education: Aplastic Anemia. *Oncologist* **1**, 187-189.
- Tewari, M., Quan, L.T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D.R., Poirier, G.G., Salvesen, G.S. & Dixit, V.M. (1995): Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. *Cell* **81**, 801-809.
- Thompson, C.B. (1995): Apoptosis in the pathogenesis and treatment of disease. *Science* **267**, 1456-1462.
- Thornberry, N.A., Rano, T.A., Peterson, E.P., Rasper, D.M., Timkey, T., Garcia-Calvo, M., Houtzager, V.M., Nordstrom, P.A., Roy, S., Vaillancourt, J.P., Chapman, K.T. & Nicholson, D.W. (1997): A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. *J Biol Chem* **272**, 17907-17911.
- Tichelli, A., Gratwohl, A., Nissen, C. & Speck, B. (1994): Late clonal complications in severe aplastic anemia. *Leuk Lymphoma* **12**, 167-175.
- Tichelli, A., Gratwohl, A., Wuersch, A., Nissen, C. & Speck, B. (1988): Antilymphocyte globulin for myelodysplastic syndrome. *Br J Haematol* **68**, 139-140.
- Timmer, T., de Vries, E.G. & de Jong, S. (2002): Fas receptor-mediated apoptosis: a clinical application? *J Pathol* **196**, 125-134.

- Tong, W.M., Cortes, U. & Wang, Z.Q. (2001a): Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. *Biochim Biophys Acta* **1552**, 27-37.
- Tong, W.M., Hande, M.P., Lansdorp, P.M. & Wang, Z.Q. (2001b): DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression. *Mol Cell Biol* **21**, 4046-4054.
- Tuzuner, N., Cox, C., Rowe, J.M., Watrous, D. & Bennett, J.M. (1995): Hypocellular myelodysplastic syndromes (MDS): new proposals. *Br J Haematol* **91**, 612-617.
- Uren, A.G., Pakusch, M., Hawkins, C.J., Puls, K.L. & Vaux, D.L. (1996): Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. *Proc Natl Acad Sci USA* **93**, 4974-4978.
- van Leeuwen, F.E. (1996): Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. *Baillieres Clin Haematol* **9**, 57-85.
- Vaquez, M. & Aubertin, C. (1904): L'anémie pernicieuse d'après les conceptions actuelles. *Bull Mem Soc Med Hop Paris* **21**, 288-297.
- Villa, P., Kaufmann, S.H. & Earnshaw, W.C. (1997): Caspases and caspase inhibitors. *Trends Biochem Sci* **22**, 388-393.
- Wallace, P.K., Palmer, L.D., Perry-Lalley, D., Bolton, E.S., Alexander, R.B., Horan, P.K., Yang, J.C. & Muirhead, K.A. (1993): Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells. *Cancer Res* **53**, 2358-2367.
- Weaver, V.M., Carson, C.E., Walker, P.R., Chaly, N., Lach, B., Raymond, Y., Brown, D.L. & Sikorska, M. (1996): Degradation of nuclear matrix and DNA cleavage in apoptotic thymocytes. *J Cell Sci* **109**, 45-56.
- Williams, G.T. & Smith, C.A. (1993): Molecular regulation of apoptosis: genetic controls on cell death. *Cell* **74**, 777-779.
- Wolf, B.B. & Green, D.R. (1999): Suicidal tendencies: apoptotic cell death by caspase family proteinases. *J Biol Chem* **274**, 20049-20052.
- Wyllie, A.H. & Golstein, P. (2001): More than one way to go. *Proc Natl Acad Sci U S A* **98**, 11-13.
- Wyllie, A.H., Kerr, J.F. & Currie, A.R. (1980): Cell death: the significance of apoptosis. *Int Rev Cytol* **68**, 251-306.
- Yamamoto, T., Shichishima, T., Shikama, Y., Saitoh, Y., Ogawa, K. & Maruyama, Y. (2002): Granulocytes from patients with paroxysmal nocturnal hemoglobinuria and normal individuals have the same sensitivity to spontaneous apoptosis. *Exp Hematol* **30**, 187-194.
- Yoshida, Y., Anzai, N. & Kawabata, H. (1995): Apoptosis in myelodysplasia: a paradox or paradigm. *Leuk Res* **19**, 887-891.
- Young, N.S. (1995): Aplastic anemia. *The Lancet* **346**, 228-232
- Yu, L.X., Jia, Y.B. & Zhang, Y. (2002): Management of acute rejection of kidney allograft. *Di Yi Jun Yi Da Xue Xue Bao* **22**, 752-754.
- Yuan, C., Ding, Z. & Cheng, Y. (2002): Caspases and Apoptosis. *Chin Med J* **115**, 14-17.
- Yuan, J., Shaham, S., Ledoux, S., Ellis, H.M. & Horvitz, H.R. (1993): The *C. elegans* cell death gene *ced-3* encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. *Cell* **75**, 641-652

- Yunis, J.J., Lobell, M., Arnesen, M.A., Oken, M.M., Mayer, M.G., Rydell, R.E. & Brunning, R.D. (1988): Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. *Br J Haematol* **68**, 189-194.
- Zoumbos, N.C., Gascon, P., Djeu, J.Y., Trost, S.R. & Young, N.S. (1985a): Circulating activated suppressor T lymphocytes in aplastic anemia. *N Engl J Med* **312**, 257-265.
- Zoumbos, N.C., Gascon, P., Djeu, J.Y. & Young, N.S. (1985b): Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. *Proc Natl Acad Sci U S A* **82**, 188-192.

## 7.2 Eigene Publikationen

- Schrezenmeier, H., Kneifel, C., Rojewski, M., Mönich, T., Schwartz, S. & Thiel, E. (2000a): Induction of apoptosis by arsenic trioxide in acute myeloid leukemia blasts in vitro. *Onkologie* **23**, 91.
- Schrezenmeier, H., Mönich, T., Rojewski, M., Kneifel, C. & Thiel, E. (2000b): Induction of Apoptosis in myeloid cells by antithymocyte globulin: implications for its efficacy in aplastic anemia and myelodysplastic syndrome? *Onkologie* **23**, 48.
- Schrezenmeier, H., Mönich, T., Rojewski, M. & Thiel, E. (2001): Effects of antithymocyte globulin in myeloid cells: induction of apoptosis, activation of caspases and inhibition of proliferation rate. *Onkologie* **24**, 53.